The MAPS Executive Consortium details how Medical Affairs will drive the evolution of industry to match the needs of a changing society.
“I see Medical Affairs co-leading the pharmaceutical and MedTech industries into a new era of patient-centered evidence generation and communication in a valued-based world,” Kremer says.
Kesselring will work with the MAPS Professional Development Committee to assist with the creation of courses supporting 7 Medical Affairs competency certification tracks identified in the MAPS 5-year strategic plan.
This white paper addresses insights challenges in Strategy, Data Generation, and Analysis/Reporting – arming Medical Affairs teams with the tools and opportunity to build strategies that preempt these challenges.
This white paper by the MAPS Field Medical FAWG details strategies for optimizing your Field Medical team for the OmniChannel World
This white paper by the MAPS Medical Communications FAWG details strategies for using modular content to increase the efficiency and accuracy of medical and scientific content to enable omnichannel engagement strategy.
Over the last decade as the requirements for evidence to support the various dimensions of value assessment of medicines have strengthened and the breadth of audiences has increased, Medical Affairs is realizing more potential and bringing together its capabilities for strategy, science, and communication in powerful ways. In the rapidly evolving regulatory, technological, and scientific environment, the Medical Affairs function is uniquely positioned to coordinate the identification, prioritization, strategic planning, execution and communication of the broad variety of high-quality evidence necessary to fulfill unmet needs of clinicians, payers, reimbursement agencies, policy makers, advocacy groups, and patients.
This Standard and Guidance is intended to inform learners about the Evidence Generation function, strategic direction, and operations across multiple geographies.
The growth of Real-World Evidence (RWE) from sources including patient registries, claims data, electronic medical records, digital health technologies and more has powered the ability of Medical Affairs to drive patient outcomes. Here, the MAPS Executive Consortium describes how.
MAPS is pleased to share our 2023 Medical Metrics Benchmarking Report, based on findings from 51 leading organizations representing the Pharmaceutical, Biotech, and Medical and Diagnostic Device sectors.
MAPS announces the election of Dr. Danie du Plessis as Chair of the MAPS Board of Directors. Du Plessis is currently Executive Vice-President (EVP) & Head of Medical Affairs at Kyowa Kirin International and is a senior pharmaceutical executive with 30 years’ experience.